Episode 164: PREMIUM Stuff you really need to know about HDL, ASA and metformin
In episode 164, Mike and James finally get to another PREMIUM episode and boy is it ever premium. We discuss the latest HDL raising drugs, ASA after a DVT, and a new meta-analysis of metformin. With our usual skill, alacrity and boyish charm we give all our premium listeners their monies worth with practice changing evidence.
Show notes
1) Dalcetrapib (HDL raising) study stopped due to no benefit
2) Genetic HDL – no reduction in heart disease
Lancet doi:10.1016/S0140-6736(12)60312-2
3) WARFASA – Aspirin for Preventing the Recurrence of Venous Thromboembolism
4) A new metformin meta-analysis – is it good or bad?
PLoS Med 9(4): e1001204. doi:10.1371/journal.pmed.1001204
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
